Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Submembranous cytoskeletons stabilize nodes of Ranvier.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.
Self-Reported Fatigue and Energy Cost During Walking Are Not Related in Patients With Multiple Sclerosis.
Patients feeling severely affected by multiple sclerosis: How do patients want to communicate about end-of-life issues?
ICV-transplanted human glial precursor cells are short-lived yet exert immunomodulatory effects in mice with EAE.
Time to see the light.
MAIT cells in autoimmunity.
Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning.
Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
The role of growth factors as a therapeutic approach to demyelinating disease.
A genome-wide association study in progressive multiple sclerosis.
Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis.
Prevalence of stress urinary incontinence in women with multiple sclerosis.
NAD⁺ in aging, metabolism, and neurodegeneration.
Can we overcome the 'clinico-radiological paradox' in multiple sclerosis?
Endogeneous Remyelination: Findings in Human Studies.
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis.
Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.
Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy.
Cortical lesion load correlates with diffuse injury of multiple sclerosis normal appearing white matter.
Is multiple sclerosis an autoimmune disease?
Effect of Glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
The next generation of exoskeletons: lighter, cheaper devices are in the works.

Pages